Mesalamine (Mesalazine)Third Party Manufacturing in India

Mesalamine, also known as mesalazine or 5-aminosalicylic acid (5-ASA), works by exerting a topical anti-inflammatory effect on the colonic mucosa. After oral administration, the delayed-release formulation protects the drug from premature absorption in the stomach and small intestine, delivering the active moiety directly to the terminal ileum and colon, where inflammatory bowel disease activity is concentrated. Once released, mesalamine inhibits cyclooxygenase and lipoxygenase pathways within the colonic epithelium, reducing the production of prostaglandins and leukotrienes that drive mucosal inflammation. It also acts as a potent free radical scavenger, neutralizing reactive oxygen species produced by activated neutrophils and macrophages at sites of inflammation. Mesalamine inhibits the activation of nuclear factor kappa-B (NF-κB), a key transcription factor that regulates the expression of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-8 (IL-8). Additionally, it activates peroxisome proliferator-activated receptor-gamma (PPAR-γ) in colonic epithelial cells, further suppressing the inflammatory cascade. By reducing the infiltration of inflammatory cells and decreasing cytokine production, mesalamine helps restore the integrity of the colonic mucosal barrier and reduces the clinical symptoms of active inflammatory bowel disease.

Therapeutic Uses

Mesalamine is prescribed for:

• Ulcerative Colitis (Active and Maintenance): Treating mild to moderate active ulcerative colitis and maintaining remission in patients with quiescent disease across all colonic segments.
• Crohn's Disease (Mild to Moderate): Managing inflammatory activity in selected cases of Crohn's colitis, particularly when disease is limited to the colon.
• Proctitis and Proctosigmoiditis: Treating localized inflammation of the rectum and distal colon, often in combination with topical mesalamine formulations.
• Pouchitis Prevention: Maintaining remission in patients who have undergone ileal pouch-anal anastomosis surgery.

Why Manufacturers Choose Mesalamine

Mesalamine is the gold-standard first-line therapy for inflammatory bowel disease and is prescribed for the long-term management of ulcerative colitis, ensuring a consistent and predictable demand. The drug's position as a maintenance therapy means patients require continuous refills, creating strong repeat-purchase volumes. The delayed-release formulation (DR) is the most technically demanding version to manufacture, requiring advanced enteric coating technologies such as Eudragit-based pH-dependent coatings that precisely control drug release. This technical complexity creates a barrier to entry and allows established WHO-GMP manufacturers to offer premium contract manufacturing services at competitive margins. The range of strengths from 250 mg to 1.2 g allows manufacturers to serve both the initiation and maintenance dosing spectrum. Indian manufacturers meeting USFDA, MHRA, or WHO-GMP standards can access high-value regulated markets globally.

This makes Mesalamine one of the most sought-after gastrointestinal molecules for third party manufacturing in India.